🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In a recent Pharmafocus interview, Dewpoint CEO Ameet Nathwani shares his thoughts on the current landscape of diabetes therapies. Read to learn how #condensates play a role in disease progression and may be targeted with a new generation of therapeutics: pharmafocus.com/collections/ph…

See a promising example of a condensate-modifying drug that inhibits tumor growth in the recent nature paper from The Conrad Lab showing FSP1 inhibition via relocalization to condensates, which induces ferroptosis in cancer cells. nature.com/articles/s4158…

Published today in Nature Communications - our efforts to better understand the prevalence of biomolecular condensate formation amongst fusion oncoproteins found in a range of diverse cancers. rdcu.be/dneM5

Congratulations team on this exciting and valuable resource, demonstrating the broad implications of aberrant condensation in oncology!

Dewpoint co-founder Richard Young, board member Regina Barzilay, head of Cancer Biology Ann Boija & team published in Nature Chemical Biology how deep learning predicts specific partitioning of small molecules in #condensates with distinct chemical environments: nature.com/articles/s4158…

In the last 5 years, Dewpoint has made huge progress evolving and applying the science of condensates towards therapeutic discovery. Read our latest article to hear more from our CSO Isaac Klein bit.ly/45YJ9mn

Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Advance Oncology Pipeline - Read more: dewpointx.com/dewpoint-thera…

At last week’s annual ASHG meeting, Dewpoint scientist Ruoyu Tian shared our advances in identifying the role of #condensates in common diseases and their related traits. #ASHG23 See the Reviewers’ Choice poster for more details: dewpointx.com/rare-missense-…

We are pleased to share Dewpoint CSO Isaac Klein’s Drug Discovery World podcast about the intersection of #condensate science and therapeutic development. Isaac brings his unique perspective as a physician-scientist to solving complex biological puzzles and advancing drug discovery.

Read our latest Journal of Molecular Biology perspective by Erik Martin, Christiane Iserman, Balaji Olety, Diana Mitrea & Isaac Klein reviewing the role of #condensates in the viral replication cycle and discussing novel strategies to target them for novel antiviral therapies: sciencedirect.com/science/articl…

Our newest perspective discussing opportunities in targeting #condensates as a new class of antivirals is now in press Journal of Molecular Biology with Dewpoint Therapeutics

Today we announced multiple patent applications on novel composition of matter for the treatment of ALS, “a significant leap forward in our mission to redefine the treatment of diseases deemed intractable or difficult to treat” Read the Press Release: dewpointx.com/dewpoint-thera…

Don't miss Drago Milovanovic 's upcoming Kitchen Table Talk, on October 30th! Registration is open at condensates.com

Dr. Jesse Lai will present on October 9 at the Society for Neuroscience’s Neuroscience 2024 conference. Join him to find out how a #condensate modulating drug reverses markers of #ALS pathology, by targeting a #condensatopathy shared by ~97% of patients. sfn.org/meetings/neuro…

Why is Dewpoint Therapeutics One to Watch? Revolutionary #condensate science with applicability across therapeutic areas, an #AI-powered state-of-the-art platform, unrivaled expertise, and a culture that nourishes growth and innovation. thepharmaletter.com/ones-to-watch/…

Another major milestone for Dewpoint: the nomination of DPTX3186 as the first condensate modulating development candidate, for the treatment of Wnt-driven cancers. DPTX3186 c-mod inhibits the function of a historically ‘undruggable’ target – beta catenin. tinyurl.com/4s49ruve

Our next Kitchen Table Talk is tomorrow, October 30, with Dragomir Milovanovic, Principal Investigator - Molecular Neuroscience, German Center for Neurodegenerative Diseases. Join us to learn about “Condensate biology at the synapse”. Register here: condensates.com/resources/drag…

Great coverage in The Pharma Letter about a major milestone for Dewpoint – the nomination of our first development candidate, DPTX3186, as a potential therapeutic agent for the treatment of Wnt-driven cancers. Read the article: thepharmaletter.com/major-mileston…

Our lab's latest News & Views in Nature Chemistry analyzes key findings from Thody et al: physicochemical properties, not structure, drive small molecule partitioning into biomolecular condensates. Important implications for drug development! Kriwacki Lab nature.com/articles/s4155…

Announcing the nomination of DPTX3496, the second #cmod development candidate that targets the oncogenic driver function of beta catenin in Wnt-driven cancers. IND-enabling studies are progressing and IND filing is planned for the second half of the year. tinyurl.com/26xde734